Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Alexander Levitzki is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR
Pettikiriarachchi, A., Ugolev, Y., Birkinshaw, R., Wardak, A., Faux, M. C., Adams, T. E., Joubran, S., Shir, A., Edinger, N., Zigler, M., Levitzki, A. & Burgess, A. W., May 2026, In: PLoS ONE. 21, 5 May, e0334584.Research output: Contribution to journal › Article › peer-review
Open Access -
Targeted apoptotic immune modulator for the treatment of metastatic EGFR-positive solid tumors
Broka, D., Klein, S., Shir, A., Schade, B., Saxena, M., Dasargyri, A., Jarzebinska, A., De Feyter, C., Bajic, D., Colecchia, D., D'Amico, L., Kitas, E., Hikri, E., Skowicki, M. J., Okoniewski, M. J., Baldino, L., Qeriqi, B., de Stanchina, E., Schreiber, J. & Buchi, M. & 9 others, , 3 Jun 2025, In: Proceedings of the National Academy of Sciences of the United States of America. 122, 22, e2500489122.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer
Levitzki, A. & Klein, S., 11 Jun 2019, In: Proceedings of the National Academy of Sciences of the United States of America. 116, 24, p. 11579-11586 8 p.Research output: Contribution to journal › Article › peer-review
Open Access18 Scopus citations -
Impact of the anticancer drug nt157 on tyrosine kinase signaling networks
Su, S. P., Flashner-Abramson, E., Klein, S., Gal, M., Lee, R. S., Wu, J., Levitzki, A. & Daly, R. J., May 2018, In: Molecular Cancer Therapeutics. 17, 5, p. 931-942 12 p.Research output: Contribution to journal › Article › peer-review
14 Scopus citations -
S101, an Inhibitor of Proliferating T Cells, Rescues Mice from Superantigen-Induced Shock
Shir, A., Klein, S., Sagiv-Barfi, I., Geiger, T., Zigler, M., Langut, Y., Edinger, N. & Levitzki, A., 15 Jan 2018, In: Journal of Infectious Diseases. 217, 2, p. 288-297 10 p.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations